Evidence map›Paper›PMID 31636342›Full record

Trial reportLeukemia2020

Rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: long-term follow-up of a phase 2 study from the German Hodgkin Study Group.

Dennis A Eichenauer, Annette Plütschow, Michael Fuchs, Sylvia Hartmann, Martin-Leo Hansmann, Boris Böll, Bastian von Tresckow, Peter Borchmann, Andreas Engert

Abstract readClinical Trial, Phase IILetter
PubMed Publisher
In one paragraph

Trial report in Leukemia, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Individualized patient care in nodular lymphocyte-predominant Hodgkin lymphoma.Hematology. American Society of Hematology. Education Program · 2022
    Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Dennis A EichenauerFirst Department of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, University of Cologne, Cologne, Germany.
Annette PlütschowFirst Department of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, University of Cologne, Cologne, Germany.
Michael FuchsFirst Department of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, University of Cologne, Cologne, Germany.
Sylvia HartmannSenckenberg Institute of Pathology, University Hospital Frankfurt, Frankfurt, Germany.ORCID http://orcid.org/0000-0003-3424-1091
Martin-Leo HansmannSenckenberg Institute of Pathology, University Hospital Frankfurt, Frankfurt, Germany.
Boris BöllFirst Department of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, University of Cologne, Cologne, Germany.
Bastian von TresckowFirst Department of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, University of Cologne, Cologne, Germany.
Peter BorchmannFirst Department of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, University of Cologne, Cologne, Germany.
Andreas EngertFirst Department of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, University of Cologne, Cologne, Germany. a.engert@uni-koeln.de.
University of Cologne · DEGoethe University Frankfurt · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdultAgedAntigens, CD20Disease ProgressionFemaleFollow-Up StudiesGermanyHodgkin DiseaseHumansLymphocytesMaleMiddle AgedNeoplasm Recurrence, LocalProgression-Free SurvivalProspective StudiesRetrospective StudiesAntigens, CD20Rituximab

Identifiers

PMID31636342
OpenAlexW2980730194

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.